• Environmental Analysis Health and Toxicology
• /
• v.14 no.3
• /
• pp.113-120
• /
• 1999

Fluorination of drinking water has been used world widely to reduce the incidence of caries. Recently, contradictory results on the cytotoxicity of fluoride compounds are reported. In addition, there are attempts to use fluorosilicate for fluorination of drinking water in Korea, therefore, we tried to analyze the cytotoxicity of fluoride compounds on oral epidermoid carcinoma (KB and A253) and osteosarcoma (HOS and MG-63) cells in this study. We treated cells with 0, 10, 50 and 250 ppm of fluorosilicic acid (domestic or from Fluka, F$\_$6/H$_2$Si), sodium fluorosilicate (F$\_$6/Na$_2$Si), sodium fluoroacetate (FCH$_2$CO$_2$Na), sodium fluoride (NaF) or potassium fluoride(KF) and measured the relative cell survival by MTT assay. At the concentration of < 10ppm, no significant cytotoxicity was observed. At 50 ppm, each cells revealed different response to fluoride treatment. Among cells used in this study, MG-63 was the most resistant to fluoride treatment. Comparable toxicity data from domestic and imported fluorosilicic acids were obtained. When we compared the relative cytotoxicity of fluoride compounds against their fluoride contents, the differences in relative cell survival were smaller. Most of cells showed < 20% of survival at 250 ppm. In order to analyze the pH dependence of the cytotoxicity of fluorosilicates, the pH of cell culture media containing fluorosilicate was adjusted to 7.4 or 6.5 and the relative cytotoxicity was measured. At lower pH, about 10% higher cytotoxicity was obtained. Thus, our data suggested that the toxicity of domestic fluorosilicic acid was similar to that of fluorosilicic acid from Fluka, and the cytotoxicity of fluoride compounds was dependent on the relative content of fluoride and pH.

• The Journal of Korean Academy of Prosthodontics
• /
• v.46 no.6
• /
• pp.620-627
• /
• 2008

STATEMENT OF PROBLEM: A biochemical approach for surface modification has offered an alternative for physicochemical and morphological methods to obtain desirable bone-implant interfaces. PURPOSE: The purpose of the present study was to investigate cell responses to poly (D,L-lactide-co-glycolide) (PLGA)/$1{\alpha}$,25-(OH)$_2D_3$ coating with reference to cellular proliferation and differentiation in vitro. MATERIAL AND METHODS: 96 titanium discs were fabricated and divided into four groups. Group 1 was anodized under 300 V as control. Group 2, 3 and 4 were anodized then coated with 3 ml PLGA/$1{\alpha}$,25-(OH)$_2D_3$ solutions. Amount of the solutions were 2 ul, 20 ul and 200ul respectively. The osteoblast-like Human Osteogenic Sarcoma (HOS) cells were seeded and cultured for 1, 3 and 7 days. MTSbased cell proliferation assay and ALPase activity test were carried out. RESULTS: PLGA nanoparticles were observed as fine, smooth and round and HOS cells attached to the anodized surfaces through strand-like and sheet-like filopodia. After 3 days of culture, the dendritic filopodia were exaggerated and sheet-like cytoplasmic projections covered the coated titanium surfaces. After 3 days of culture, all of the groups showed increased cellular proliferation and the lowest proliferation rate was measured on group 2. Higher amount of incorporated $1{\alpha}$,25-(OH)$_2D_3$ (Group 3 and 4) improved cellular proliferation but the differences were not significant statistically (P > .05). But they increased the rate of ALP activities than the control group at day 3 (P < .05). CONCLUSION: Biodegradable PLGA nanoparticles incorporated with vitamin D metabolite positively affected proliferation and differentiation of cells on the anodized titanium surface.

• Journal of Oral Medicine and Pain
• /
• v.36 no.1
• /
• pp.11-20
• /
• 2011

Valproic acid (VPA) is a well-known anticonvulsive agent and has been used in the treatment of epilepsy for almost 30 years. VPA emerged in 1997 as an antineoplastic agent. And it is known that antitmor activity of VPA is associated with its targeted at histone deacetylases. 17AAG, Inhibition of HSP90 leads to the proteasome degradation of the HSP90 client proteins, such as Akt, Raf/Ras, Erk, VEGF, cyclin D and p53, and causes potent antitumor activity. It is reported that 17AAG-induced HSP90 inhibition results in prevention of cell proliferation and induction of apoptosis in several types of cancer. This study was undertaken to investigate the synergistic apoptotic effect of co-treatment with the histone deacetylases inhibitor, VPA and the HSP90 inhibitor, 17AAG on human osteosarcoma (HOS) cells. Cell viability was evaluated by trypan-blue exclusion. Induction and augmentation of apoptosis were confirmed by Hoechst staining, flow cytometry (DNA hypoploidy and MMP change), Westen blot analysis and immunofluorescent staining. In this study, HOS cells co-treated with VPA and 17AAG showed several lines of apoptotic manifestation such as nuclear condensations, the reduction of MMP, the decrease of DNA content, the release of cytochrome c into cytosol, the translocation of AIF onto nuclei, and activation of caspase-3, caspase-7 and PARP whereas each single treated HOS cells did not. Although the single treatment of 1 mM VPA or 0.5 ${\mu}M$ 17AAG for 48 h did not induce apoptosis, the co-treatment with them induced prominently apoptosis. Therefore our data in this study provide the possibility that combination therapy with VPA and 17AAG could be considered as a novel therapeutic strategy for human osteosarcoma.

• BMB Reports
• /
• v.33 no.3
• /
• pp.263-267
• /
• 2000

We cloned $hda1^+$ (histone deacetylase 1) of fission yeast Schizosaccharomyces pombe. The hda1 of S. pombe was previously reported to encode for an active histone deacetylase (Rundlett et al., 1996; Olsson et al., 1998). The $hda1^+$ is phylogenetically related to the new open reading frame HOS2 of Saccharomyces cerevisiae and only shows a partial homology to the well-known histone deacetylase subclasses, RPD3 and HDA1. A single hda1 mRNA of 1.8 kb was detected at the same level in actively growing and nitrogen-starved cells. When highly over-expressed in S. pombe from an inducible promoter, $hda1^+$ inhibited cell proliferation and caused defects in morphology and cell division. The increased histone deacetylase activity was detected in hdar over-expressing cells. These results suggest that the Hda1p should function on the regulation of cell division possibly by (Allfrey, 1966) direct deacetylation of cytoskeletal (Wade et al., 1997) and cell division regulatory proteins, (Wolffe, 1997) or by controlling their gene expressions.

• Clinical and Experimental Pediatrics
• /
• v.59 no.9
• /
• pp.374-380
• /
• 2016

Purpose: Patients with unresectable, relapsed, or refractory osteosarcoma need a novel therapeutic agent. Metformin is a biguanide derivative used in the treatment of type II diabetes, and is recently gaining attention in cancer research. Methods: We evaluated the effect of metformin against human osteosarcoma. Four osteosarcoma cell lines (KHOS/NP, HOS, MG-63, U-2 OS) were treated with metformin and cell proliferation was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cell cycle progression and apoptosis were evaluated using flow cytometric analysis, and migration and wound healing assay were performed. Fourteen female Balb/c-nude mice received KHOS/NP cell grafts in their thigh, and were allowed access to metformin containing water (2 mg/mL) ad libitum. Tumor volume was measured every 3-4 days for a period of 4 weeks. Results: Metformin had a significant antiproliferative effect on human osteosarcoma cells. In particular, metformin inhibited the proliferation and migration of KHOS/NP cells by activation of AMP-activated protein kinase and consequent inhibition of the mammalian target of rapamycin pathway. It also inhibited the proliferation of cisplatin-resistant KHOS/NP clone cells. Analysis of KHOS/NP xenograft Balb/c-nude models indicated that metformin displayed potent in vivo antitumor effects. Conclusion: Further studies are necessary to explore metformin's therapeutic potential and the possibilities for its use as an adjuvant agent for osteosarcoma.

• Korean Journal of Food Science and Technology
• /
• v.23 no.5
• /
• pp.561-567
• /
• 1991

This study was designed to investigate the productivity of L-methionine by the method of protoplast fusion between Brevibacterium flavum ATCC 14067 and Corynebacterium glutamicm ATCC 13032, and then L-methionine production was performed to continuous fermentation using the immobilized fusant cells. Mutants B. flavum K 104($thr\;met\;Km^{r}\;Et^{r}\;Sm^{r}\;Tm^{r}\;as\;genetic\;marker$) and C. glutamicum B 70($thr\;Hos\;Km^{r}\;Et^{r}\;Sm^{r}\;Tm^{r}as\;genetic\;marker$) were isolated by MNNG treatment. On the other hand, protoplast of mutants were formed to treat with lysis solution containing $500{\mu}g/ml$ of lysozyme. The ratios of protoplast formation and regeneration were 99% and $64{\sim}66%$ respectively. Fusion frequency between B. flavum K 104 and C. glutamicum B 70 showed the $3.5{\times}10^{5}$ in the 35% polyethylene glycol(PEG6000) containing 3% PVP solution. The productivity of L-methionine by fusant BFCG 37 immobilized with sodium alginate was 0.89 g/l the batch fermentation and was $18.75mg/^{1}hr\;^{1}$ on the continuous fermentation at $30^{\circ}C$ for 72 hr.